Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma.
Betea, Daniela; Bradwell, A. R.; Harvey, T. C.et al.
2004 • In Journal of Clinical Endocrinology and Metabolism, 89 (7), p. 3413-20
Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma..pdf
[en] Parathyroid carcinoma is a rare cause of primary hyperparathyroidism, and the efficacy of medical therapy and chemo- and radiotherapy is poor in recurrent or metastatic disease. We report the first case of PTH immunization in which tumor shrinkage accompanied hormonal, biochemical, and clinical improvements in a patient with metastatic parathyroid carcinoma.A 50-yr-old woman with refractory parathyroid carcinoma and pulmonary metastases was immunized eight times between February 2001 and December 2003 with bovine and modified human PTH fragments and intact human PTH, mixed with Freund's adjuvant. Total and ionized calcium and PTH levels were assayed weekly for 6 months and regularly thereafter. Thoracic computed tomography scans were performed regularly.Antibodies to all PTH fragments were detected after two immunizations. Baseline PTH and total calcium were 213.0 ng/liter and 13.96 mg/dl, respectively, and remained elevated during the first three immunizations. From the fourth immunization onward, PTH and calcium decreased, and the patient's clinical condition improved markedly. PTH and calcium levels have remained controlled for more than 24 months, and the sizes (surface area) of pulmonary metastases decreased from baseline by 39-71%.This is the first evidence that PTH immunization not only can improve clinical, hormonal, and biochemical measures in parathyroid carcinoma but also has an antitumor effect.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Betea, Daniela ; Centre Hospitalier Universitaire de Liège - CHU > Endocrinologie clinique
Daly, Adrian ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
English
Title :
Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid carcinoma.
Publication date :
July 2004
Journal title :
Journal of Clinical Endocrinology and Metabolism
ISSN :
0021-972X
eISSN :
1945-7197
Publisher :
Endocrine Society, Chevy Chase, United States - Maryland
Kebebew E 2001 Parathyroid carcinoma. Curr Treat Options Oncol 2:347-354
Szabo J, Heath B, Hill VM, Jackson CE, Zarbo RJ, Mallette LE, Chew SL, Besser GM, Thakker RV, Huff V, et al 1995 Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am J Hum Genet 56:944-950
Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H, Teh BT 2003 HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40:657-663
Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo LO, Larsson C, Arnold A 2003 Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349:1722-1729
Kebebew E, Arici C, Duh QY, Clark OH 2001 Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg 136:878-885
Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ 1998 Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83:1083-1088
Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, McCary LC, Olson KA, Turner SA, Peacock M 2003 The effects of cinacalcet HCl (AMG 073) on serum calcium levels in patients with parathyroid carcinoma or recurrent primary HPT after PTX. J Bone Miner Res 18(Suppl 1):S171 (Abstract)
Rubin M, Sliney J, McCary LC, Silverberg SJ, Bilezikian JP 2003 Effective management of severe hypercalcemia with the calcimimetic cinacalcet HCl in patients with parathyroid carcinoma. J Bone Miner Res 18(Suppl 1):S392 (Abstract)
Bradwell AR, Harvey TC 1999 Control of hypercalcaemia of parathyroid carcinoma by immunisation. Lancet 353:370-373
Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, Moss PA 2002 Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 169:1984-1992
Mead GP, Harvey T, Epstein M, Beckers A, Bradwell AR, Hypercalcaemia of parathyroid carcinoma controlled by immunotherapy. Program of the 84th Annual Meeting of The Endocrine Society, San Francisco, CA, 2002, p 93 (Abstract OR21-3)
Mosca PJ, Clay TM, Kim Lyerly H, Morse MA 2003 Current status of dendritic cell immunotherapy of malignancies. Int Rev Immunol 22:255-281
Schott M, Feldkamp J, Schattenburg D, Krueger T, Dozenrath C, Seissler J, Scherbaum WA 2000 Induction of cellular immunity in a parathyroid carcinoma treated with tumor lysate-pulsed dendritic cells. Eur J Endocrinol 142:300-306
Schott M, Feldkamp J, Lettmann M, Simon D, Scherbaum WA, Seissler J 2001 Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin Endocrinol (Oxf) 55:271-277
Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schuller G, Benko T, Niederle B, Brostjan C, Jakesz R, Gnant M 2002 Mar stimulation of autologous antitumor T cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells. J Clin Endocrinol Metab 87:1098-1104
Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S 2003 Tumors as elusive targets of T cell-based active immunotherapy. Trends Immunol 24:335-342
Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G 2003 Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD 2002 Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998
Buckley KA, Wagstaff SC, McKay G, Gaw A, Hipskind RA, Bilbe G, Gallagher JA, Bowler WB 2001 Parathyroid hormone potentiates nucleotide-induced [Ca 2+]i release in rat osteoblasts independently of Gq activation or cyclic monophosphate accumulation. A mechanism for localizing systemic responses in bone. J Biol Chem 276:9565-9571
McCauley LK, Koh AJ, Beecher CA, Rosol TJ 1997 Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells. Endocrinology 138:5427-5433
Kotzmann H, Koller M, Abela C, Clodi M, Riedl M, Graninger W, Niederle B, Luger A 1998 Effects of parathyroid hormone and serum calcium on the phenotype and function of mononuclear cells in patients with primary hyperparathyroidism. Eur J Clin Invest 28:353-358
Tzanno-Martins C, Futata E, Jorgetti V, Duarte AJ 2000 Restoration of impaired T cell proliferation after parathyroidectomy in hemodialysis patients. Nephron 84:224-227
Ozdemir F, Sezer S, Ozdemir B, Arat Z, Yakupoglu U, Turan M, Haberal M 2002 Influence of parathyroid hormone level on renal allograft outcome, and correlation with histopathological findings. Tissue Antigens 60:552